Last reviewed · How we verify
Placebo to Telcagepant
Placebo to Telcagepant is a CGRP receptor antagonist Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Acute treatment of migraine attacks with or without aura.
Telcagepant is a calcitonin gene-related peptide receptor antagonist.
Telcagepant is a calcitonin gene-related peptide receptor antagonist. Used for Acute treatment of migraine attacks with or without aura.
At a glance
| Generic name | Placebo to Telcagepant |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals. This leads to a reduction in migraine frequency and severity.
Approved indications
- Acute treatment of migraine attacks with or without aura
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) (PHASE2, PHASE3)
- A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) (PHASE2)
- Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) (PHASE3)
- A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) (PHASE1)
- Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) (PHASE3)
- MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) (PHASE2)
- Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) (PHASE3)
- Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Telcagepant CI brief — competitive landscape report
- Placebo to Telcagepant updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to Telcagepant
What is Placebo to Telcagepant?
How does Placebo to Telcagepant work?
What is Placebo to Telcagepant used for?
Who makes Placebo to Telcagepant?
What drug class is Placebo to Telcagepant in?
What development phase is Placebo to Telcagepant in?
What are the side effects of Placebo to Telcagepant?
What does Placebo to Telcagepant target?
Related
- Drug class: All CGRP receptor antagonist drugs
- Target: All drugs targeting CGRP receptor
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute treatment of migraine attacks with or without aura
- Compare: Placebo to Telcagepant vs similar drugs
- Pricing: Placebo to Telcagepant cost, discount & access